Búsqueda | BVS CLAP/SMR-OPS/OMS

1.

Survival and clinical outcomes of patients with melanoma brain metastasis in the era of checkpoint inhibitors and targeted therapies.

Vosoughi, Elham; Lee, Jee Min; Miller, James R; Nosrati, Mehdi; Minor, David R; Abendroth, Roy; Lee, John W; Andrews, Brian T; Leng, Lewis Z; Wu, Max; Leong, Stanley P; Kashani-Sabet, Mohammed; Kim, Kevin B.

BMC Cancer ; 18(1): 490, 2018 04 27.

Artículo en Inglés | MEDLINE | ID: mdl-29703161

2.

Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial.

Hodi, F Stephen; Chesney, Jason; Pavlick, Anna C; Robert, Caroline; Grossmann, Kenneth F; McDermott, David F; Linette, Gerald P; Meyer, Nicolas; Giguere, Jeffrey K; Agarwala, Sanjiv S; Shaheen, Montaser; Ernstoff, Marc S; Minor, David R; Salama, April K; Taylor, Matthew H; Ott, Patrick A; Horak, Christine; Gagnier, Paul; Jiang, Joel; Wolchok, Jedd D; Postow, Michael A.

Lancet Oncol ; 17(11): 1558-1568, 2016 Nov.

Artículo en Inglés | MEDLINE | ID: mdl-27622997

3.

Phase 2 Study of Intralesional PV-10 in Refractory Metastatic Melanoma.

Thompson, John F; Agarwala, Sanjiv S; Smithers, B Mark; Ross, Merrick I; Scoggins, Charles R; Coventry, Brendon J; Neuhaus, Susan J; Minor, David R; Singer, Jamie M; Wachter, Eric A.

Ann Surg Oncol ; 22(7): 2135-42, 2015 Jul.

Artículo en Inglés | MEDLINE | ID: mdl-25348780

4.

Extended long-term follow-up of metastatic melanoma patients treated with immunotherapy: late relapses and second primary melanomas.

Minor, David R; Kim, Kevin B; Karuturi, R Krishna M; Kashani-Sabet, Mohammed.

Front Oncol ; 13: 1241917, 2023.

Artículo en Inglés | MEDLINE | ID: mdl-38111529

5.

Yttrium-90 radioembolization of renal cell carcinoma metastatic to the liver.

Abdelmaksoud, Mohamed H K; Louie, John D; Hwang, Gloria L; Kothary, Nishita; Minor, David R; Sze, Daniel Y.

J Vasc Interv Radiol ; 23(3): 323-30.e1, 2012 Mar.

Artículo en Inglés | MEDLINE | ID: mdl-22277275

6.

A Pilot Study of Hepatic Irradiation with Yttrium-90 Microspheres Followed by Immunotherapy with Ipilimumab and Nivolumab for Metastatic Uveal Melanoma.

Minor, David R; Kim, Kevin B; Tong, Ricky T; Wu, Max C; Kashani-Sabet, Mohammed; Orloff, Marlana; Eschelman, David J; Gonsalves, Carlin F; Adamo, Robert D; Anne, Pramila R; Luke, Jason J; Char, Devron; Sato, Takami.

Cancer Biother Radiopharm ; 37(1): 11-16, 2022 Feb.

Artículo en Inglés | MEDLINE | ID: mdl-35021863

7.

Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis.

Tarhini, Ahmad A; Kang, Ni; Lee, Sandra J; Hodi, F Stephen; Cohen, Gary I; Hamid, Omid; Hutchins, Laura F; Sosman, Jeffrey A; Kluger, Harriet M; Eroglu, Zeynep; Koon, Henry B; Lawrence, Donald P; Kendra, Kari L; Minor, David R; Lee, Carrie B; Albertini, Mark R; Flaherty, Lawrence E; Petrella, Teresa M; Streicher, Howard; Sondak, Vernon K; Kirkwood, John M.

J Immunother Cancer ; 9(5)2021 05.

Artículo en Inglés | MEDLINE | ID: mdl-33963015

8.

Prevalence of Homologous Recombination Pathway Gene Mutations in Melanoma: Rationale for a New Targeted Therapeutic Approach.

Kim, Kevin B; Soroceanu, Liliana; de Semir, David; Millis, Sherri Z; Ross, Jeffrey; Vosoughi, Elham; Dar, Altaf A; Nosrati, Mehdi; Desprez, Pierre-Yves; Ice, Ryan; Chen, Michelle; Chetal, Kashish; Bhattacharjee, Anukana; Moretto, John; Leong, Stanley P; Singer, Mark I; Parrett, Brian M; Minor, David R; McAllister, Sean; Miller, James R; Salomonis, Nathan; Kashani-Sabet, Mohammed.

J Invest Dermatol ; 141(8): 2028-2036.e2, 2021 08.

Artículo en Inglés | MEDLINE | ID: mdl-33610559

9.

Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609.

Tarhini, Ahmad A; Lee, Sandra J; Hodi, F Stephen; Rao, Uma N M; Cohen, Gary I; Hamid, Omid; Hutchins, Laura F; Sosman, Jeffrey A; Kluger, Harriett M; Eroglu, Zeynep; Koon, Henry B; Lawrence, Donald P; Kendra, Kari L; Minor, David R; Lee, Carrie B; Albertini, Mark R; Flaherty, Lawrence E; Petrella, Teresa M; Streicher, Howard; Sondak, Vernon K; Kirkwood, John M.

J Clin Oncol ; 38(6): 567-575, 2020 02 20.

Artículo en Inglés | MEDLINE | ID: mdl-31880964

10.

Prognostic factors in metastatic melanoma patients treated with biochemotherapy and maintenance immunotherapy.

Minor, David R; Moore, Dan; Kim, Christine; Kashani-Sabet, Mohammed; Venna, Suraj S; Wang, Wei; Boasberg, Peter; O'Day, Steven.

Oncologist ; 14(10): 995-1002, 2009 Oct.

Artículo en Inglés | MEDLINE | ID: mdl-19776094

11.

gp100 peptide vaccine in melanoma.

Minor, David R.

N Engl J Med ; 365(8): 771; author reply 771, 2011 08 25.

Artículo en Inglés | MEDLINE | ID: mdl-21864189

12.

Prolonged survival after intraperitoneal interleukin-2 immunotherapy for recurrent ovarian cancer.

Minor, David R; Moores, Samantha P; Chan, John K.

Gynecol Oncol Rep ; 22: 43-44, 2017 Nov.

Artículo en Inglés | MEDLINE | ID: mdl-29034306

13.

Risk of bleeding not increased by sorafenib or sunitinib.

Minor, David R.

Lancet Oncol ; 11(2): 112-3; author reply 113, 2010 Feb.

Artículo en Inglés | MEDLINE | ID: mdl-20152763

14.

A retrospective study of biochemotherapy for metastatic melanoma: the importance of dose intensity.

Minor, David R; Madland, Michael T; Kashani-Sabet, Mohammed; Denny, Susan R; Harvey, William B.

Cancer Biother Radiopharm ; 20(5): 479-86, 2005 Oct.

Artículo en Inglés | MEDLINE | ID: mdl-16248763

15.

Risk of venous thromboembolism with bevacizumab in cancer patients.

Minor, David R.

JAMA ; 301(14): 1434; author reply 1435-6, 2009 Apr 08.

Artículo en Inglés | MEDLINE | ID: mdl-19351937

16.

Case Report of a Pregnancy During Ipilimumab Therapy.

Mehta, Andrew; Kim, Kevin B; Minor, David R.

J Glob Oncol ; 4: 1-3, 2018 09.

Artículo en Inglés | MEDLINE | ID: mdl-30241195

17.

Successful desensitization in a case of Stevens-Johnson syndrome due to vemurafenib.

Minor, David R; Rodvien, Robert; Kashani-Sabet, Mohammed.

Melanoma Res ; 22(5): 410-1, 2012 Oct.

Artículo en Inglés | MEDLINE | ID: mdl-22828249

18.

Sunitinib therapy for melanoma patients with KIT mutations.

Minor, David R; Kashani-Sabet, Mohammed; Garrido, Maria; O'Day, Steven J; Hamid, Omid; Bastian, Boris C.

Clin Cancer Res ; 18(5): 1457-63, 2012 Mar 01.

Artículo en Inglés | MEDLINE | ID: mdl-22261812

19.

Releasing the brake on the immune system: ipilimumab in melanoma and other tumors.

Tarhini, Ahmad; Lo, Ernest; Minor, David R.

Cancer Biother Radiopharm ; 25(6): 601-13, 2010 Dec.

Artículo en Inglés | MEDLINE | ID: mdl-21204754

20.

Severe gastrointestinal toxicity with administration of trametinib in combination with dabrafenib and ipilimumab.

Minor, David R; Puzanov, Igor; Callahan, Margaret K; Hug, Bruce A; Hoos, Axel.

Pigment Cell Melanoma Res ; 28(5): 611-2, 2015 Sep.

Artículo en Inglés | MEDLINE | ID: mdl-25996827

BVS CLAP/SMR-OPS/OMS

Centro Latinoamericano de Perinatología, Salud de la Mujer y Reproductiva

Configurar filtros

Su selección (0)

Formato de exportación:

Exportar:

Survival and clinical outcomes of patients with melanoma brain metastasis in the era of checkpoint inhibitors and targeted therapies.

Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial.

Phase 2 Study of Intralesional PV-10 in Refractory Metastatic Melanoma.

Extended long-term follow-up of metastatic melanoma patients treated with immunotherapy: late relapses and second primary melanomas.

Yttrium-90 radioembolization of renal cell carcinoma metastatic to the liver.

A Pilot Study of Hepatic Irradiation with Yttrium-90 Microspheres Followed by Immunotherapy with Ipilimumab and Nivolumab for Metastatic Uveal Melanoma.

Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis.

Prevalence of Homologous Recombination Pathway Gene Mutations in Melanoma: Rationale for a New Targeted Therapeutic Approach.

Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609.

Prognostic factors in metastatic melanoma patients treated with biochemotherapy and maintenance immunotherapy.

gp100 peptide vaccine in melanoma.

Prolonged survival after intraperitoneal interleukin-2 immunotherapy for recurrent ovarian cancer.

Risk of bleeding not increased by sorafenib or sunitinib.

A retrospective study of biochemotherapy for metastatic melanoma: the importance of dose intensity.

Risk of venous thromboembolism with bevacizumab in cancer patients.

Case Report of a Pregnancy During Ipilimumab Therapy.

Successful desensitization in a case of Stevens-Johnson syndrome due to vemurafenib.

Sunitinib therapy for melanoma patients with KIT mutations.

Releasing the brake on the immune system: ipilimumab in melanoma and other tumors.

Severe gastrointestinal toxicity with administration of trametinib in combination with dabrafenib and ipilimumab.